Shares of Israel's BioLineRx plunged 51% this morning when the biotech announced that it was shutting down a Phase II/III study for an experimental schizophrenia treatment--its lead program--after an interim analysis forced the company to acknowledge that investigators were headed for a failure.
Gilead Sciences has invoked Cancer Genetics to head up international clinical trials in an effort to diagnose patients with chronic lymphocytic leukemia.
In 2011 the U.S. government ran a war game to simulate how a San Francisco-sized city would cope with an anthrax attack by terrorists.
Sunshine Biopharma is eyeing a Phase I trial of its Adva-27a treatment for drug-resistant breast cancer, and the company is in talks to find a CMO partner.
India's government is taking seriously the call to better regulate clinical trials, and now the country is planning to launch two independent committees tasked with overseeing the process.
A U.K. court has convicted a former Aptuit employee of manipulating data from hundreds of safety studies, making investigational drugs seem successful when they weren't.
Earlier this month, Radiant Research exited the CRO business, as parent company Clinical Research Advantage shipped out its drug development arm. Now the company is focusing on its remaining core business: maintaining and expanding a network of clinical trial sites.
Two private equity firms are pooling their CRO resources, agreeing to merge the formerly public BioClinica with imaging and cardiac safety contractor CoreLab.
Shares of Beijing-based Sinovac Biotech soared 30% this morning after investigators reported promising Phase III data on its EV71 vaccine, designed to protect infants from hand, foot and mouth disease. But an analyst tells reporters that the party may be premature if competing vaccines now in development prove effective in ongoing late-stage trials.
After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning, Bloomberg reported.